← Leaderboards
Markus H. Kuehn
Iowa City Va Medical Center
$5,217,731
Attributed
$6,756,660
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $733.9K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,756,660 · 4
VA$0 · 5
By mechanism
R01$6,756,660 · 4
I01$0 · 4
I50$0 · 1
Top collaborators
- Stanislav Y Emelianov7 shared
- C Ross Ethier7 shared
- Randy H. Kardon7 shared
- Matthew M. Harper5 shared
Most similar at Iowa City Va Medical Center
Same institution · by research overlap
- Randy H. Kardon$1,763,261
- Matthew M. Harper$0
Others in their field
Top investigators on “Blindness”
- Randall J Bateman · Washington University$137,189,188
- John M Lachin · George Washington University$122,970,601
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- Beth Baseler · Leidos Biomedical Research, Inc.$111,479,515
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$96,562,493
Research focus
BlindnessGlaucomaInnovationVisionCellsPrimary Open Angle GlaucomaAffectMediatingEye DiseasesPhysiologic Intraocular PressureIowaVeteransDesignExpectationQuality Of LifeMonitorMyocilinTissuesClinically RelevantRetinaStructureCell DeathLaboratoriesFunctional Disorder
Grant awards (39)
T-cell mediated RGC damage in glaucoma$623,953
R01 · FY2025 · EY · contact PI
Evaluating the interaction of the immune system and inflammation on the progression of blast-mediatedneurodegeneration.$0
I01 · FY2025 · VA
Center for the Prevention and Treatment of Visual Loss$0
I50 · FY2025 · VA
T-cell mediated RGC damage in glaucoma$635,231
R01 · FY2024 · EY · contact PI
T-cell mediated RGC damage in glaucoma Diversity Initiative Supplement$92,498
R01 · FY2024 · EY · contact PI
Center for the Prevention and Treatment of Visual Loss$0
I50 · FY2024 · VA
Center for the Prevention and Treatment of Visual Loss$0
I50 · FY2024 · VA
Evaluating the interaction of the immune system and inflammation on the progression of blast-mediatedneurodegeneration.$0
I01 · FY2024 · VA
Translational Studies toward Cell Therapy for Treatment of Primary Open Angle Glaucoma$0
I01 · FY2024 · VA · contact PI
T-cell mediated RGC damage in glaucoma$531,459
R01 · FY2023 · EY · contact PI
Evaluating the interaction of the immune system and inflammation on the progression of blast-mediated neurodegeneration.$0
I01 · FY2023 · VA
Magnetic Steering and Longitudinal Visualization of Stem Cells for Trabecular Meshwork Therapy in Glaucoma$498,222
R01 · FY2022 · EY
Magnetic Steering and Longitudinal Visualization of Stem Cells for Trabecular Meshwork Therapy in Glaucoma$77,785
R01 · FY2022 · EY
Center for the Prevention and Treatment of Visual Loss$0
I50 · FY2022 · VA
Center for the Prevention and Treatment of Visual Loss$0
I50 · FY2022 · VA
Evaluating the interaction of the immune system and inflammation on the progression of blast-mediated neurodegeneration.$0
I01 · FY2022 · VA
Magnetic Steering and Longitudinal Visualization of Stem Cells for Trabecular Meshwork Therapy in Glaucoma$498,394
R01 · FY2021 · EY
Magnetic Steering and Longitudinal Visualization of Stem Cells for Trabecular Meshwork Therapy in Glaucoma$75,451
R01 · FY2021 · EY
Evaluating the interaction of the immune system and inflammation on the progression of blast-mediated neurodegeneration.$0
I01 · FY2021 · VA
Bioassay to Predict the Development and Progression of Glaucoma$0
I01 · FY2021 · VA · contact PI
Magnetic Steering and Longitudinal Visualization of Stem Cells for Trabecular Meshwork Therapy in Glaucoma$531,506
R01 · FY2020 · EY
Magnetic Steering and Longitudinal Visualization of Stem Cells for Trabecular Meshwork Therapy in Glaucoma$77,785
R01 · FY2020 · EY
Center for the Prevention and Treatment of Visual Loss$0
I50 · FY2020 · VA
Bioassay to Predict the Development and Progression of Glaucoma$0
I01 · FY2020 · VA · contact PI
Magnetic Steering and Longitudinal Visualization of Stem Cells for Trabecular Meshwork Therapy in Glaucoma$549,251
R01 · FY2019 · EY
Center for the Prevention and Treatment of Visual Loss$0
I50 · FY2019 · VA
Bioassay to Predict the Development and Progression of Glaucoma$0
I01 · FY2019 · VA · contact PI
Bioassay to Predict the Development and Progression of Glaucoma$0
I01 · FY2018 · VA · contact PI
Stem Cell Therapy for Glaucoma$0
I01 · FY2017 · VA · contact PI
Stem Cell Therapy for Glaucoma$0
I01 · FY2016 · VA · contact PI
Stem Cell Therapy for Glaucoma$0
I01 · FY2015 · VA · contact PI
Stem Cell Therapy for Glaucoma$0
I01 · FY2015 · VA · contact PI
Unfolded Protein Response in Glaucoma Pathogenesis$369,950
R01 · FY2014 · EY · contact PI
Unfolded Protein Response in Glaucoma Pathogenesis$358,625
R01 · FY2013 · EY · contact PI
Unfolded Protein Response in Glaucoma Pathogenesis$377,500
R01 · FY2012 · EY · contact PI
The Role of Complement System in Glaucoma$356,400
R01 · FY2012 · EY · contact PI
The Role of Complement System in Glaucoma$356,400
R01 · FY2011 · EY · contact PI
The Role of Complement System in Glaucoma$371,250
R01 · FY2010 · EY · contact PI
The Role of Complement System in Glaucoma$375,000
R01 · FY2009 · EY · contact PI